Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Preliminary Study Assessing the Feasibility of Estimating and Determining Amyloid Burden from Florbetapir PET Images without Using Target and Reference Regions based on the Deep Learning 3D Convolutional Neural Network Approach

Next Previous
Trial Profile

A Preliminary Study Assessing the Feasibility of Estimating and Determining Amyloid Burden from Florbetapir PET Images without Using Target and Reference Regions based on the Deep Learning 3D Convolutional Neural Network Approach

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Florbetapir F 18 (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Diagnostic use

Most Recent Events

  • 05 Oct 2018 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top